Navigation Links
New Cancer “Growth Blocking Super Drug” Patents Filed
Date:2/8/2013

San Diego, CA (PRWEB) February 08, 2013

The pharmaceutical world has been racing for the cure for cancer for decades with what most experts agree is limited success. The current drugs are either so toxic and damaging to the body that many patients have to weigh the benefits of their use or the drugs are only designed to treat specific types of cancers and often only specific “strains” of specific cancers.

There is now an emerging world class sprinter in the race to create the “Super Drug” – Kalos Therapeutics. The “Super Drug” in the cancer world refers to a drug that may be used to treat multiple types of cancer and their various strains while avoiding the additional trauma often caused by chemotherapy, radiation and many of the current cancer drugs.

Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (Atrial Natriuretic Peptide) family of peptides as a new mechanism for the treatment of cancer.

Kalos is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.

George Colberg, the CEO of Kalos Therapeutics, has amassed a who’s who dream team representing the best and brightest of the cancer and bio-tech worlds. More importantly is the fact that the team has the ability to think differently about what is the most effective way to treat cancer. It is that difference in thinking that appears to be producing a game changing cancer therapy.

Anti-Cancer Bio-technology

“Kalos has successfully leveraged the natural antiproliferative activity of the Atrial Natriuretic Peptide (ANP) family of peptides in our pat
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
2. Transcreener Assays Highlighted for Challenging Microbial, Cancer and Epigenetic Drug Targets at SLAS 2013
3. Governor Cuomo Announces Continued Growth at Roswell Park Cancer Institute with Regional Economic Development Council Funding; RPCI Center for Personalized Medicine established with CTG (NASDAQ: CTGX) serving as its technology partner
4. Transition in cell type parallels treatment response, disease progression in breast cancer
5. Two University of Colorado Cancer Center Studies Show that Silibinin, Found in Milk Thistle, Protects Against UV-Induced Skin Cancer
6. Navigating Cancer Announces Jeff Oberlander as VP, Engineering
7. Tracking the Battle Against Breast Cancer With New Market Research
8. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
9. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
10. Touch Medical Media Splits From Touch Briefings, Launches a Series of Cutting Edge, Free to Access, Educational Resources and Signs an Updated Media Partnership With ECCO, The European CanCer Organisation Representing 60,000 Oncology Professionals
11. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Kitware, a leader ... tool that enables the exploration of hospital costs ... in response to the recent release of “Medicare Provider ... top 100 most-billed procedures from the Centers for Medicare ... for similar procedures at hospitals across the country has ...
(Date:5/17/2013)... May 17, 2013 Topricin Pain ... Inc., has been listed among nationally recommended over-the-counter ... initiative conducted by "U.S. News" Health in collaboration ... the “No. 1 Pharmacists Recommended designation” in ... national OTC brands, and is the only homeopathic ...
(Date:5/17/2013)... world-leading provider of scientific, technical and medical information products ... study in Reproductive BioMedicine Online ... an abnormal chromosomal composition can be identified by the ... classifying the risk of genetic abnormality without a biopsy. ... a retrospective study, using their predictive model to assess ...
(Date:5/17/2013)... , May 17, 2013  Yongye International, Inc. (NASDAQ: ... leading developer, manufacturer, and distributor of crop nutrient products ... , today announced that, on May 16, 2013, the ... directors (the "Board of Directors") was provided a letter ... Hong Kong ) Limited ("Abax") to Full Alliance ...
Breaking Biology Technology:Kitware Enables Interactive Exploration of CMS Medicare Data 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Breakthrough for IVF? 2Breakthrough for IVF? 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... 5 , - Data Presented ... York , ThromboGenics NV (Euronext Brussels: ... innovative medicines for eye,disease, vascular disease and cancer, today announces ... the treatment of,Diabetic Macular Edema (MIVI II DME). The data ...
... , LA JOLLA, Calif., Oct. 5 Transdel Pharmaceuticals, Inc. ... a conference call and audio webcast on Tuesday, October 6, ... of its Phase 3 clinical study for Ketotransdel®, a topical ... A press release will be issued on Tuesday, October 6, ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
Cached Biology Technology:ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 4Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 2Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4
(Date:5/19/2013)... have engineered a strain of electricity-producing bacteria that can ... and carbon dioxide as its sole source of carbon. ... their findings at the 113th General Meeting of the ... result of current production solely on hydrogen," says Amit ... his co-authors are part of the Lovley Lab Group ...
(Date:5/18/2013)... presented today at Digestive Disease Week (DDW) explores new ... impact of coffee on autoimmune disease and palliative care ... has been associated with reduced risk of fibrosis, a ... of java each month also correlate with lower risk ... Mayo Clinic, Rochester, MN, linked coffee consumption with reduced ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... a mile below the ocean surface donot bother ... to one spot. Fornourishment, they rely completely onsymbiotic ... sulphurous volcanicsoup in which they both thrive. , ... bacteria-free, with a completedigestive system. Juveniles swim, hunt, ...
... in some animals to periodically wake up while hibernating may ... researchers at Penn State. The finding could offer an insight ... and has potential implications for human health. , ... part of a unique strategy to get past harsh winters ...
... It may be possible to protect the testes of cancer ... scientist told the 22nd annual conference of the European Society ... Tuesday 20 June 2006. Mr. Alon Carmely from ... for the first time that the injection of a drug ...
Cached Biology News:Giant deep-sea tubeworm's meal ticket comes in as a skin infection 2Giant deep-sea tubeworm's meal ticket comes in as a skin infection 3Breaks in hibernation help fight bugs 2Injection may prevent infertility in men receiving cancer chemotherapy 2